InvestSMART

Neurotech International Limited (ASX: NTI) - Announcements

Current share price for NTI : $0.016 0.001 (5.88%)+

ASX company news and announcements for Neurotech International Limited (NTI) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurotech International Limited (NTI) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurotech International Limited (NTI), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurotech International Limited (NTI)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 Secondary Trading Notice 18 Sep 2023 9:46AM $0.063 $0.016 fallen by 74.60%
$26 Application for quotation of securities - NTI 18 Sep 2023 9:23AM $0.063 $0.016 fallen by 74.60%
$26 Proposed issue of securities - NTI 15 Sep 2023 4:58PM $0.063 $0.016 fallen by 74.60%
$26 Clinician Briefing Presentation and Webcast 15 Sep 2023 9:53AM $0.057 $0.016 fallen by 71.93%
$26 Proposed issue of securities - NTI 15 Sep 2023 9:26AM $0.057 $0.016 fallen by 71.93%
$26 Appointment of Corporate Advisor 15 Sep 2023 9:10AM $0.057 $0.016 fallen by 71.93%
$26 Upcoming Clinician Briefing 11 Sep 2023 9:00AM $0.051 $0.016 fallen by 68.63%
$26 Last Patient Completes Treatment in NTIPANS1 Clinical Trial 31 Aug 2023 8:22AM $0.050 $0.016 fallen by 68%
$26 Appendix 4G and Corporate Governance Statement 30 Aug 2023 5:52PM $0.050 $0.016 fallen by 68%
$26 Appendix 4E & Annual Report 30 Aug 2023 5:52PM $0.050 $0.016 fallen by 68%
$26 Application for quotation of securities - NTI 8 Aug 2023 4:23PM $0.048 $0.016 fallen by 66.67%
$26 Proposed issue of securities - NTI 4 Aug 2023 1:22PM $0.052 $0.016 fallen by 69.23%
$26 Disclosure Document 4 Aug 2023 1:11PM $0.052 $0.016 fallen by 69.23%
$26 First Patient Treated in Rett Syndrome Clinical Trial 1 Aug 2023 1:12PM $0.056 $0.016 fallen by 71.43%
$26 Quarterly Activities/Appendix 4C Cash Flow Report 26 Jul 2023 9:22AM $0.059 $0.016 fallen by 72.88%
$26 Notice of Quarterly Investor Conference Call 19 Jul 2023 9:19AM $0.059 $0.016 fallen by 72.88%
$26 NTI Receives HREC Approval for Rett Syndrome Clinical Trial 10 Jul 2023 9:17AM $0.046 $0.016 fallen by 65.22%
$26 Notification of cessation of securities - NTI 30 Jun 2023 5:06PM $0.040 $0.016 fallen by 60%
$26 Notification regarding unquoted securities - NTI 28 Jun 2023 4:14PM $0.033 $0.016 fallen by 51.52%
$26 NTI to Present at Rett Syndrome Foundation Meeting 5 Jun 2023 8:27AM $0.042 $0.016 fallen by 61.90%
$26 Results of Meeting 1 Jun 2023 6:50PM $0.040 $0.016 fallen by 60%
$26 NTI Granted 2 Year Extension of Treatment for ASD Patients 31 May 2023 9:22AM $0.045 $0.016 fallen by 64.44%
$26 NTI granted HREC Approval for PANDAS/PANS Trial Extension 30 May 2023 9:23AM $0.047 $0.016 fallen by 65.96%
$26 Notification of cessation of securities - NTI 16 May 2023 4:46PM $0.049 $0.016 fallen by 67.35%
$26 NTI Completes Recruitment in PANDAS/PANS Clinical Trial 3 May 2023 9:11AM $0.050 $0.016 fallen by 68%

226 - 250 of 700 results

Page 10 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.